Skip to main content
. Author manuscript; available in PMC: 2012 Feb 1.
Published in final edited form as: Cancer Gene Ther. 2011 May 6;18(8):563–570. doi: 10.1038/cgt.2011.23

Figure 3. GILZ inhibition increases phagocytic capacity of DCs.

Figure 3

BMDCs were cultured, gene modified with either control (labeled CTRL) or with the siGILZ. Cultures were maintained in DC medium and analyzed at days 6, 8, and 10 of development, as shown. PE-labeled OVA (20 μg/ml) was added for 1 hour, and cells were stained for CD11c and Annexin V. Shown are summaries of the percentages of live CD11c+ cells that phagocytosed labeled peptide (identified by PE-positive cells). The bars are gated on GFP+ fractions of control vs siRNA-GILZ. Significant differences (p<.05, paired t tests with control) are marked with an asterisk: GILZ inhibition at days 8 and 10 led to an increase in phagocytosis compared to control. Three different experiments are combined in the graph and the two conditions for each timepoint are shown.